TR199902786T2 - Streamline the cell structure of lipophilic peptides to streamline immune system activity and stop inflammation. - Google Patents

Streamline the cell structure of lipophilic peptides to streamline immune system activity and stop inflammation.

Info

Publication number
TR199902786T2
TR199902786T2 TR1999/02786T TR9902786T TR199902786T2 TR 199902786 T2 TR199902786 T2 TR 199902786T2 TR 1999/02786 T TR1999/02786 T TR 1999/02786T TR 9902786 T TR9902786 T TR 9902786T TR 199902786 T2 TR199902786 T2 TR 199902786T2
Authority
TR
Turkey
Prior art keywords
cells
streamline
activity
lymphocytic
inhibiting
Prior art date
Application number
TR1999/02786T
Other languages
Turkish (tr)
Inventor
Buelow Roland
Grassy Gerard
Calas Bernard
Original Assignee
Sangstat Medical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/028,083 external-priority patent/US6696545B1/en
Application filed by Sangstat Medical Corporation filed Critical Sangstat Medical Corporation
Publication of TR199902786T2 publication Critical patent/TR199902786T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Novel oligonucleotides comprising a sequence derived by a computer program are provided for inhibiting cytotoxic activity of lymphocytic cells, inhibiting production of inflammatory cytokines and inflammatory responses associated with those cytokines, inhibiting the activity of heme-containing enzymes and delaying the onset of an autoimmune disease. By combining the subject compositions with mixtures of cells comprising lymphocytic cells and cells which would otherwise activate the lymphocytic cells, lysis of the target cells can be substantially inhibited. The oligopeptides may be joined to a variety of other groups or compounds for varying the activity of the subject composition. The subject compositions may be administered by any convenient means to inhibit lymphocytic attack on tissue, particularly involved with xenogeneic or allogeneic transplants or to inhibit the production of inflammatory cytokines and inflammatory responses associated therewith. The subject compositions may also be used in the inhibition of the activity of heme-containing enzymes.
TR1999/02786T 1997-04-11 1998-04-10 Streamline the cell structure of lipophilic peptides to streamline immune system activity and stop inflammation. TR199902786T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83891697A 1997-04-11 1997-04-11
US09/028,083 US6696545B1 (en) 1997-04-11 1998-02-23 Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Publications (1)

Publication Number Publication Date
TR199902786T2 true TR199902786T2 (en) 2000-06-21

Family

ID=26703275

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02786T TR199902786T2 (en) 1997-04-11 1998-04-10 Streamline the cell structure of lipophilic peptides to streamline immune system activity and stop inflammation.

Country Status (14)

Country Link
US (1) US7267822B2 (en)
EP (1) EP0973799B1 (en)
JP (1) JP4550171B2 (en)
CN (1) CN1216900C (en)
AT (1) ATE352556T1 (en)
AU (2) AU761717B2 (en)
BR (1) BR9808529B1 (en)
CA (1) CA2286478A1 (en)
IL (1) IL132310A0 (en)
NO (1) NO994898L (en)
NZ (1) NZ500287A (en)
PL (1) PL336302A1 (en)
TR (1) TR199902786T2 (en)
WO (1) WO1998046633A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773240B1 (en) 1997-12-30 2002-11-29 Synt Em PROCESS FOR PREDICTING, IDENTIFYING AND DESCRIBING MOLECULES LIKELY TO PRESENT RESEARCH BEHAVIOR, ESPECIALLY IN THE FIELD OF PHARMACY AND MOLECULES OBTAINED BY THIS PROCESS
WO2000063350A2 (en) * 1999-04-21 2000-10-26 The University Of Georgia Research Foundation, Inc. Cysteine protease and inhibitors for prevention and treatment of neurocysticerocosis
CA2474056A1 (en) * 2002-01-24 2003-07-31 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
JP2005524650A (en) * 2002-02-26 2005-08-18 サングスタット メディカル コーポレイション Method of treating gastrointestinal toxicity induced by cell destruction therapy and composition for treatment
FR2842738B1 (en) * 2002-07-23 2006-02-10 Negma Lerads USE OF A RHEINE FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF CHRONIC INFLAMMATION, THE PREVENTION AND TREATMENT OF REJECTION OF ORGAN AND TISSUE TRANSPLANTATION
EP1594519A4 (en) * 2002-11-15 2006-08-16 Sangstat Medical Corp Cytomodulating peptides for treating interstitial cystitis
WO2005009457A1 (en) * 2003-05-15 2005-02-03 Sangstat Medical Corporation Rdp58 compositions and methods for inhibiting vascularization of cell populations
WO2005001075A1 (en) * 2003-05-15 2005-01-06 Sangstat Medical Corporation Rdp58 compositions and methods for modulating the activity of osteoclasts and osteoblasts
WO2005053727A2 (en) 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
CN104231054A (en) * 2014-09-01 2014-12-24 王跃建 1L-10 polypeptide inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723128A (en) 1987-01-30 1998-03-03 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides
DE3854300T2 (en) 1987-01-30 1996-01-11 Univ Leland Stanford Junior LYMPHOCYTE INHIBITION BY HLA PEPTIDES.
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
US5385888A (en) 1987-03-20 1995-01-31 The Regents Of The University Of California Class I MHC modulation or surface receptor activity
EP0459978B1 (en) 1989-03-03 1997-07-16 The Regents Of The University Of California Class i mhc modulation of surface receptor activity
IL102964A0 (en) * 1991-08-26 1993-01-31 Cytel Corp Hla-restricted hepatitis b virus ctl epitopes
EP0661985B1 (en) 1991-11-08 1999-07-07 The Board Of Trustees Of The Leland Stanford Junior University Peptides capable of binding cd8 molecules on ctl precursors
US5440015A (en) 1992-07-21 1995-08-08 Glycomed Incorporated Selectin peptide medicaments for treating disease
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
WO1995013288A1 (en) * 1993-11-10 1995-05-18 The Board Of Trustees For The Leland Stanford Junior University Surface membrane proteins and their effect on immune response
US5686070A (en) * 1994-03-03 1997-11-11 Genentech, Inc. Methods for treating bacterial pneumonia
ES2168456T3 (en) * 1995-01-16 2002-06-16 North Sydney Area Health Serv PEPTIDES AFFECTING T-LYMPHOCYTES
US6162434A (en) 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
WO1997024140A1 (en) 1996-01-02 1997-07-10 The Board Of Trustees Of Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
US6436903B1 (en) 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
AU3209897A (en) 1996-05-24 1997-12-09 Board Of Trustees Of The Leland Stanford Junior University Immunomodulating dimers
US6696545B1 (en) * 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation

Also Published As

Publication number Publication date
NO994898D0 (en) 1999-10-08
US7267822B2 (en) 2007-09-11
EP0973799B1 (en) 2007-01-24
BR9808529B1 (en) 2010-10-05
AU2003244571B2 (en) 2007-07-05
ATE352556T1 (en) 2007-02-15
JP4550171B2 (en) 2010-09-22
AU761717B2 (en) 2003-06-05
NZ500287A (en) 2002-10-25
JP2001526641A (en) 2001-12-18
NO994898L (en) 1999-11-24
CN1259958A (en) 2000-07-12
IL132310A0 (en) 2001-03-19
AU6897898A (en) 1998-11-11
BR9808529A (en) 2000-10-24
AU2003244571A1 (en) 2003-10-02
EP0973799A1 (en) 2000-01-26
CN1216900C (en) 2005-08-31
US20040248810A1 (en) 2004-12-09
CA2286478A1 (en) 1998-10-22
WO1998046633A1 (en) 1998-10-22
PL336302A1 (en) 2000-06-19

Similar Documents

Publication Publication Date Title
Hong et al. Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells
TR199801168T2 (en) �nterleukin-1 beta inhibits the inhibitory enzyme.
Plaut et al. Increase in histamine receptors on thymus-derived effector lymphocytes during the primary immune response to alloantigens
TR199902786T2 (en) Streamline the cell structure of lipophilic peptides to streamline immune system activity and stop inflammation.
PT879282E (en) IMMUNOTHERAPY USING CITOTOXIC T-LYMPHOCYTES (CTL)
NO960743L (en) Cellular preparations, their preparation and therapeutic use
MX2007007259A (en) Myd88 homodimerization inhibitors.
TR199902383T2 (en) New pyrimidine derivatives and the process for their preparation.
ATE446106T1 (en) PHARMACEUTICAL COMPOSITION FOR TRIGGERING AN IMMUNE RESPONSE IN A HUMAN OR AN ANIMAL
ES2249058T3 (en) PRESERVATION FACTORS OF PROGENITING CELLS AND RELATED METHODS AND PRODUCTS.
WO1999045098A3 (en) Delivery or proteins into eukaryotic cells with recombinant yersinia
WO2001004282A3 (en) Replication-competent anti-cancer vectors
EP0959889A4 (en) Methods and compositions to inhibit keratinocyte proliferation
WO2005051978A3 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
PT1003525E (en) COMPOSITION AND METHOD FOR REGULATION OF PROLIFERATION AND CELL DEATH
IL152406A0 (en) Anti-freeze proteins, their production and use
Gallinger et al. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice
AU5168099A (en) Use of novel agents inducing cell death in synergy with interferons
UY27662A1 (en) MOCROGLY INHIBITORS TO INTERRUPT IMMUNE REACTIONS ASSOCIATED WITH INTERLEUCINE 12 AND IFNY.
WO2001036453A3 (en) Ny-eso-1 nanopeptide derivatives, and uses thereof
PT1230261E (en) Ny-eso-1 nonapeptide derivatives, and uses thereof
WO2000075291A3 (en) Cells with enforced expression of bcl-xl
Jespersen THE EFFECT OF ALPHA-FETOPROTEIN (AFP) AND OTHER CORD SERUM FRACTIONS ON MITOGEN-INDUCED LYMPHOCYTE TRANSFORMATION AND THE ONE-WAY MIXED LYMPHOCYTE REACTION.
龚为民 et al. Preliminary X-ray diffraction study on haemorrhagin AaHⅢ from snake venom of Agkistrodon acutus
Chen THYMIC INVOLVEMENT IN THE ONTOGENY OF THE B-CELL POPULATION.